Investor Presentaiton

Comprehensive Global Collaboration with Regional and Global Leading Players as Their Partner-of-Choice Collaborations with global player: Continued collaborations with global pharmaceutical and biotech companies Total deal value exceeds US$2.5bn¹ Including upfront payment of US$256m¹ Lilly ADC: co-development, in-licensed technology Synaffix connect to cure Access to Roche's bispecific antibody and Universal CART technologies Out-license ex-China global rights of up to US$ 2.1bn payments and royalties Roche Biosimilar: out-licensed Indonesia development and commercialization rights etana Biotech 3 small molecules: in-licensed Greater China rights Incyte Biosimilar: out-licensed North America development and commercialization rights Coherus BIOSCIENCES 1 pre-clinical asset: in-licensed Greater China rights ALECTOR Hanmi THE UNIVERSITY OF TEXAS MD Anderson Cancer Center Adimab Making Cancer History" loodle Hutchison Medi Pharma 00000 Collaborations with regional player: As integrated platform with validated capabilities, striving to be the best choice for partner Note: 1. Total deal value exceeds US$245m Collaborations on commercialization, Next generation TKI: co-development and commercialization rights in China BCMA CAR-T: 50:50 ownership of the asset clinical development, equity investment ค 亞盛醫藥 Ascentage Pharma Including both 2015 and 2020 strategic deals with Eli Lilly, not including royalties AnHeart Therapeutics EpimAb Biotherapeutics sirna⚫mics Advancing RNAI Therapeutics 微芯生物 CHIPSCREEN ...... Innovent Confidential Copyright©2021 Innovent Biologics 110 10

View entire presentation